<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438723</url>
  </required_header>
  <id_info>
    <org_study_id>MetCAB</org_study_id>
    <secondary_id>2011-000099-33</secondary_id>
    <nct_id>NCT01438723</nct_id>
  </id_info>
  <brief_title>The Metformin in Coronary Artery Bypass Graft (CABG) (MetCAB) Trial</brief_title>
  <acronym>MetCAB</acronym>
  <official_title>The Metformin in CABG (MetCAB) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      In patients with a myocardial infarction, occlusion of a coronary artery induces myocardial
      ischemia and cell death. If untreated, the area of myocardium exposed to this interruption in
      blood supply, will largely become necrotic. The only way to limit final infarct size, is
      timely reperfusion of the occluded artery. Paradoxically, however, reperfusion itself can
      also damage myocardial tissue and contribute to the final infarct size (&quot;reperfusion
      injury&quot;). Also during coronary artery bypass grafting (CABG), the myocardium is exposed to
      ischemia and reperfusion, which will induce cell death. Indeed, postoperatively, the plasma
      concentration of troponin I, a marker of cardiac necrosis, is increased, and associated with
      adverse outcome. The anti-hyperglycaemic drug metformin has been shown in preclinical studies
      to be able to reduce ischemia-reperfusion injury and to limit myocardial infarct size.
      Moreover, metformin therapy improves cardiovascular prognosis in patients with diabetes
      mellitus. Paradoxically, in patients with diabetes, current practice is to temporarily stop
      metformin before major surgery for the presumed risk of lactic acidosis, which is a rare
      complication of metformin. However, here is no evidence that this practice benefits the
      patient. The investigators hypothesize that pretreatment with metformin can reduce myocardial
      injury in patients undergoing elective CABG surgery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hs-Troponin-I</measure>
    <time_frame>within 24 hours after CABG</time_frame>
    <description>high sensitive cardiac troponin-I</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post operative occurrence of arrhythmias</measure>
    <time_frame>within 24 hours after CABG</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of inotropic support</measure>
    <time_frame>within two days after CABG</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to detubation</measure>
    <time_frame>within two days after CABG</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-ischemic recovery of contractile function of atrial trabeculae</measure>
    <time_frame>until 4 hours after harvesting</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day</description>
    <arm_group_label>metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>prior to CABG surgery 3 day treatment with placebo capsules three times a day</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acceptation for CABG with or without concomitant valve surgery

          -  Informed consent

          -  Age â‰¥ 18 years

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Renal dysfunction (MDRD &lt; 60 ml/min)

          -  Elevated liver enzymes (ALAT &gt; 3 times upper limit of reference range)

          -  Treatment with dipyridamole or xanthine derivatives

          -  Recent myocardial infarction (&lt;2 weeks before inclusion)

          -  Off-pump surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RUNMC</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <last_update_submitted>July 28, 2014</last_update_submitted>
  <last_update_submitted_qc>July 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemia reperfusion injury</keyword>
  <keyword>CABG</keyword>
  <keyword>metformin</keyword>
  <keyword>Hs-troponin-I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

